Tag: Prof. Peter Goadsby
Acute migraine? NICE recommends Pfizer’s rimegepant as potential option
The National Institute for Health and Care Excellence (NICE) has released conclusive draft guidance, suggesting Pfizer's Vydura (rimegepant) as a choice for treating acute...